PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic Patients.
Ya O YemchenkoViktoriya ShynkevychK Ye IshcheikinI P KaidashevPublished in: PPAR research (2020)
The immunohistochemical study allows us to show the anti-inflammatory effect of pioglitazone in psoriatic obese patients, which can be mediated by reducing the number of СD68+ macrophages, but not СD163+ macrophages, in the affected dermis.
Keyphrases
- obese patients
- bariatric surgery
- rheumatoid arthritis
- end stage renal disease
- adipose tissue
- anti inflammatory
- ejection fraction
- roux en y gastric bypass
- gastric bypass
- newly diagnosed
- disease activity
- ankylosing spondylitis
- chronic kidney disease
- weight loss
- type diabetes
- prognostic factors
- systemic lupus erythematosus